Adding Vancomycin to Cefazolin Prophylaxis Does Not Prevent Surgical Site Infections
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 18, 2023 -- The addition of vancomycin to cefazolin prophylaxis is not superior to placebo for prevention of surgical site infections in patients undergoing arthroplasty, according to a study published in the Oct. 19 issue of the New England Journal of Medicine.
Trisha N. Peel, M.B., B.S., Ph.D., from Monash University in Melbourne, Australia, and colleagues conducted a multicenter, superiority, placebo-controlled trial in which adult patients without known methicillin-resistant Staphylococcus aureus (MRSA) colonization who were undergoing arthroplasty were randomly assigned to receive 1.5 g vancomycin or normal saline placebo in addition to cefazolin prophylaxis. The modified intention-to-treat analysis included 4,113 patients: 2,233 undergoing knee arthroplasty; 1,850 undergoing hip arthroplasty; and 30 undergoing shoulder arthroplasty.
The researchers found that surgical site infections occurred in 4.5 and 3.5 percent of patients in the vancomycin and placebo groups, respectively, among the modified intention-to-treat population (relative risk, 1.28; 95 percent confidence interval, 0.94 to 1.73; P = 0.11). Surgical site infection occurred in 5.7 and 3.7 percent of patients in the vancomycin and placebo groups, respectively, among those undergoing knee arthroplasty (relative risk, 1.52; 95 percent confidence interval, 1.04 to 2.23). For those undergoing hip arthroplasty, the corresponding proportions were 3.0 and 3.1 percent (relative risk, 0.98; 95 percent confidence interval, 0.59 to 1.63). Adverse events occurred in 1.7 percent of patients in both the vancomycin group and the placebo group.
"In this pragmatic, randomized trial involving adult patients undergoing arthroplasty who had a low prevalence of MRSA colonization, the addition of vancomycin was not superior to surgical antimicrobial prophylaxis with cefazolin," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...
Few Patients With Positive Margins After Basal Cell Excision Have Recurrence
MONDAY, July 1, 2024 -- Among patients with incompletely excised basal cell carcinoma (BCC), only about 16 percent with positive histopathologic margins have clinical recurrence...
Pediatric Surgical Opioid Prescribing Concentrated Among a Few Procedures
WEDNESDAY, June 26, 2024 -- Pediatric surgical opioid prescribing is concentrated among a small number of procedures, especially tonsillectomy and/or adenectomy, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.